SEVERAL RECEPTOR TYROSINE KINASE IS ACTIVATED BUT ORCHESTRATED BY EGFR IN EGFR-TKI ACQUIRED RESISTANT LUNG ADENOCARCINOMA CELLS WITH EGFR MUTATION

被引：0

作者：

Suda, Kenichi ^{[1
]}

Mizuuchi, Hiroshi ^{[1
]}

Sato, Katsuaki ^{[1
]}

Takemoto, Toshiki ^{[1
]}

Iwasaki, Takuya ^{[1
]}

Minami, Kenji ^{[1
]}

Yatabe, Yasushi ^{[2
]}

Mitsudomi, Tetsuya ^{[1
]}

机构：

[1] Kinki Univ, Fac Med, Dept Surg, Div Thorac Surg, Higashiosaka, Osaka 577, Japan

[2] Aichi Canc Ctr, Dept Pathol & Mol Diagnost, Nagoya, Aichi, Japan

来源：

JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷

关键词：

EGFR mutation; EGFR tyrosine kinase inhibitors; acquired resistance; molecular target therapy;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P2.05-010

引用

页码：S771 / S772

页数：2

共 50 条

[1] Acquired resistance to an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in an uncommon G719S EGFR mutation
Osoegawa, Atsushi
Hashimoto, Takafumi
Takumi, Yohei
Abe, Miyuki
Yamada, Tomonori
Kobayashi, Ryoji
Miyawaki, Michiyo
Takeuchi, Hideya
Okamoto, Tatsuro
Sugio, Kenji
INVESTIGATIONAL NEW DRUGS, 2018, 36 (06) : 999 - 1005
[2] Acquired resistance to an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in an uncommon G719S EGFR mutation
Atsushi Osoegawa
Takafumi Hashimoto
Yohei Takumi
Miyuki Abe
Tomonori Yamada
Ryoji Kobayashi
Michiyo Miyawaki
Hideya Takeuchi
Tatsuro Okamoto
Kenji Sugio
Investigational New Drugs, 2018, 36 : 999 - 1005
[3] Acquired Resistance to EGFR-TKI in the Uncommon EGFR Mutation, G719S
Osoegawa, A.
Hashimoto, T.
Takumi, Y.
Kobayashi, R.
Miyawaki, M.
Takeuchi, H.
Okamoto, T.
Sugio, K.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2251 - S2251
[4] Efficacy of EGFR-TKI for Lung Adenosquamous Cell Carcinoma Harboring EGFR Mutation
Liu, Y.
Xia, X.
Du, W.
Zhang, Y.
Xu, J.
Gong, Y.
Zhu, J.
Ding, Z.
Peng, F.
Huang, M.
Xu, Y.
Wan, J.
Ren, L.
Lu, Y.
Han, B.
Wang, Y.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2380 - S2380
[5] Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma
Uramoto, Hidetaka
Shimokawa, Hidehiko
Hanagiri, Takeshi
Kuwano, Michihiko
Ono, Mayumi
LUNG CANCER, 2011, 73 (03) : 361 - 365
[6] Diverse Mechanisms of Resistance against Osimertinib, a Third-Generation EGFR-TKI, in Lung Adenocarcinoma Cells with an EGFR-Activating Mutation
Nishihara, Shigetoshi
Yamaoka, Toshimitsu
Ishikawa, Fumihiro
Ohmori, Tohru
Ando, Koichi
Kusumoto, Sojiro
Kishino, Yasunari
Manabe, Ryo
Hasebe, Yuki
Sagara, Hironori
Yoshida, Hitoshi
Tsurutani, Junji
CELLS, 2022, 11 (14)
[7] Hepatoid Adenocarcinoma of the Lung With EGFR Mutation and the Response to Tyrosine Kinase Inhibitor
Chen, H.
Wang, W.
Li, X.
Xu, C.
Zhu, Y.
Du, K.
Fang, M.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S585 - S585
[8] EGFR-TKI Alone or with Concomitant Radiotherapy for Brain Metastases in Lung Adenocarcinoma Patients with EGFR Gene Mutations
Chen, Yongshun
Yang, Jing
Li, Xue
Hao, Daxuan
Wu, Xiaoyuan
Yang, Yuanyuan
Hu, Xiaona
He, Chunyu
Wang, Wen
Liu, Jinsong
Wang, Jianhua
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S278 - S278
[9] Clinical Features and Tumor Immune Microenvironment Related to Acquired Resistance to EGFR-TKI in NSCLC Patients with EGFR Mutation
Zhang, P.
Tu, L.
Liu, R.
Xu, X.
Bao, Z.
Xu, P.
Wang, J.
Li, H.
Zhou, J.
Wang, Y.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S402 - S403
[10] Efficacy and safety of original EGFR-TKI combined with bevacizumab in advanced lung adenocarcinoma patients harboring EGFR-mutation experiencing gradual progression after EGFR-TKI treatment: a single-arm study
Long, Jianlin
Lei, Shuangyi
Wu, Zhijuan
Xiong, Shuanglong
Wang, Chunmei
Huang, Lumi
Liang, Guanzhong
Yang, Dan
Teng, Yan
Li, Yongsheng
Qi, Jun
Li, Dairong
ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (24)

← 1 2 3 4 5 →